Ranking Invest

Amicus Therapeutics, Inc.

Segmento: Healthcare Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Indicadores Básicos

Valor de Mercado

$ 2.26 Bi

IVR

-0.18

IVR2

-0.26

Índices de Previsibilidade

Faturamento

0.08

Lucro

0.53

Margem

0.88

Índices de Tendência

Faturamento

10.91

Lucro

9.31

Margem

10.05

Índices de Endividamento

DIV/PAT

1.35

DIV/L4T

-8.91

Dívida Líquida

$ 261.81 Mi

Patrimônio Líquido

$ 193.56 Mi

L4T

-$ 29.37 Mi

MM4T

-6.15%

Dívidas
Dividendos
Cotação: $7.34

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre